GlassScriptPhysician profile
Sherry L Evans
NPI 1659411064
$8,677.67
in general payments reported to CMS, 2019-2025
33 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,272 · 2022: $1,449 · 2023: $2,712 · 2024: $1,800 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,956 · Education: $1.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,955.80 |
| Education | $1.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,364.79 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $1,309.32 | 2021-2025 | Hizentra, Haegarda, Privigen |
| Amgen INC. | $926.31 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $743.95 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Blueprint Medicines Corporation | $539.75 | 2022-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $315.70 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $269.91 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Alk-Abello, INC | $216.83 | 2021-2025 | Ragwitek, Odactra, Grastek |
| Novartis Pharmaceuticals Corporation | $214.84 | 2022-2024 | |
| Glaxosmithkline, LLC. | $212.91 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Optinose US, INC. | $188.75 | 2022-2025 | |
| Pharming Healthcare, INC. | $187.48 | 2021-2025 | Ruconest |
| Kaleo, INC. | $152.16 | 2021-2024 | Auvi-Q |
| Mylan Specialty L.P. | $136.84 | 2023-2024 | Yupelri |
| Biocryst US Sales Co., LLC | $118.28 | 2025 | Orladeyo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $116.02 | 2021-2023 | Cutaquig |
| Genzyme Corporation | $115.90 | 2024-2025 | |
| Bio Products Laboratory USA, INC. | $108.04 | 2021-2022 | |
| Incyte Corporation | $57.49 | 2022-2024 | Opzelura |
| Horizon Therapeutics Plc | $44.14 | 2021-2023 | Actimmune |
| Genentech USA, INC. | $42.70 | 2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $40.61 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $38.86 | 2025 | |
| Covis Pharma Gmbh | $35.84 | 2021 | |
| Greer Laboratories, INC. | $29.71 | 2025 | Oralair |
| Tersera Therapeutics LLC | $28.70 | 2024 | Quzyttir |
| Electromed, INC. | $28.07 | 2021-2022 | |
| Abbvie INC. | $20.74 | 2024 | |
| Paratek Pharmaceuticals, INC. | $16.16 | 2025 | Xhance, Nuzyra |
| Cycle Pharmaceuticals INC | $15.93 | 2025 | Sajazir |
| Azurity Pharmaceuticals, INC. | $14.88 | 2025 | Alvesco |
| Pfizer INC. | $13.63 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.43 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.